Abstract: The instant disclosure provides a composition comprising a capsule and a fill formulation for lipophilic salts of PDE5 inhibitors. Embodiments of the fill formulation contain a liquid, lipid vehicle in which the active ingredient is dissolved and present at relatively high amounts.

Abstract: The present disclosure relates to delivery systems and methods for increasing the bioavailability and increasing the absorption rate by monolithic enteric capsule administration to humans of active ingredients compared to the bioavailability of active ingredients enterically coated for modified release or gastric protection, particularly acid sensitive active ingredients such as esomeprazole, omeprazole, and other proton pump inhibitors, systems for delivering active pharmaceutical ingredients to humans or animals via monolithic enteric capsules, and improved methods of treating gastrointestinal disorders with such methods and delivery systems.

Abstract: The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells and capsules with a functional polymer dispersion. The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells endowed with controlled release properties. The present disclosure also relates to aqueous compositions for use in the manufacture of capsule shells and capsules endowed with moisture barrier properties. The present disclosure also relates to methods of manufacturing the capsule shell and capsules, and to capsule shells and capsules obtained therewith.

Abstract: The present disclosure relates to compositions of an aqueous colloidal dispersion of hydroxypropyl methyl cellulose acetate succinate (HPMCAS), and methods for making such colloidal dispersions.

Abstract: The present disclosure relates to delivery systems and methods for increasing the bioavailability and increasing the absorption rate by monolithic enteric capsule administration to humans of active ingredients compared to the bioavailability of active ingredients enterically coated for modified release or gastric protection, particularly acid sensitive active ingredients such as esomeprazole, omeprazole, and other proton pump inhibitors, systems for delivering active pharmaceutical ingredients to humans or animals via monolithic enteric capsules, and improved methods of treating gastrointestinal disorders with such methods and delivery systems.

Abstract: The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells endowed with bulk enteric properties. The present disclosure also relates, in part, to aqueous dispersions suitable for the implementation of said manufacturing process, and to enteric capsule shells and hard capsules obtained therewith.

Abstract: The present disclosure relates to compositions of an aqueous colloidal dispersion of hydroxypropyl methyl cellulose acetate succinate (HPMCAS), and methods for making such colloidal dispersions.

Abstract: The instant disclosure provides embodiments of orally disintegrating tablet compositions that have rapid disintegrability in the oral cavity and comprise solid lipid particles enclosing at least one active ingredient to mask any unpleasant tastes associated with the active ingredient. Also provided is the process of preparing such orally disintegrating tablet pharmaceutical compositions.

Abstract: The present disclosure relates to delivery systems and methods for increasing the bioavailability and increasing the absorption rate by monolithic enteric capsule administration to humans of active ingredients compared to the bioavailability of active ingredients enterically coated for modified release or gastric protection, particularly acid sensitive active ingredients such as esomeprazole, omeprazole, and other proton pump inhibitors, systems for delivering active pharmaceutical ingredients to humans or animals via monolithic enteric capsules, and improved methods of treating gastrointestinal disorders with such methods and delivery systems.

Abstract: The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells endowed with bulk enteric properties. The present disclosure also relates, in part, to aqueous dispersions suitable for the implementation of said manufacturing process, and to enteric capsule shells and hard capsules obtained therewith.

Abstract: The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells and capsules with a functional polymer dispersion. The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells endowed with controlled release properties. The present disclosure also relates to aqueous compositions for use in the manufacture of capsule shells and capsules endowed with moisture barrier properties. The present disclosure also relates to methods of manufacturing the capsule shell and capsules, and to capsule shells and capsules obtained therewith.

Abstract: The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells endowed with bulk enteric properties. The present disclosure also relates, in part, to aqueous dispersions suitable for the implementation of said manufacturing process, and to enteric capsule shells and hard capsules obtained therewith.

Abstract: The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells endowed with bulk enteric properties. The present disclosure also relates, in part, to aqueous dispersions suitable for the implementation of said manufacturing process, and to enteric capsule shells and hard capsules obtained therewith.

Abstract: Systems and methods for modeling a compound formulation are provided.

Abstract: The present invention relates to a method of enhancing absorption of a pharmaceutical agent by administering the agent in combination with an inhibitor of BCRP/ABCG2 wherein the amount of the inhibitor is about the critical micelle concentration of the inhibitor or less than the critical micelle concentration. The invention also relates to a formulation suitable for use to enhance absorption of a pharmaceutical agent. The pharmaceutical agent can be a chemotherapeutic agent. The invention also relates to capsules containing the formulation.

Abstract: Use of an oral pharmaceutical composition to reduce the intestinal passage effect on the active principle contained in, the said composition being in the form of a system which is self-microemulsifying on contact with an aqueous phase, comprising:

Abstract: A pharmaceutical composition for oral use is disclosed. It includes, as active principle, a drug liable to undergo a strong first intestinal passage effect and a carrier which is self-micro-emulsifying on contact with an aqueous phase. The carrier includes: a therapeutically effective amount of the active principle; a lipophilic phase, which is a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with at least one fatty acid chosen from the group comprising C8-C18 fatty acids; a surfactant phase which is a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with caprylic acid (C8) and capric acid (C10); a co-surfactant phase which is an ester of a polyvalent alcohol with at least one fatty acid chosen from the group comprising caprylic esters of propylene glycol, lauric esters of propylene glycol and oleic esters of polyglycerol. A method of decreasing the effect of intestinal metabolism on a drug using the composition is also disclosed.

Abstract: The invention concerns a method for coating solid particles with a thermofusible agent which consists in: fluidizing the solid particles in an ascending air movement in spiral rotation to obtain a homogeneous individualised distribution of the particles in the air fluidized bed, the temperature of the air fluidized bed being lower than the melting point of the thermofusible agent; spraying on the particles the melted thermofusible agent in the form of atomised droplets, said droplets being distributed in a spraying cone included in an air zone, whereof the temperature enables to maintain, throughout said spraying process, a temperature of the thermofusible agent substantially equal its melting point, the spraying being carried out in the same direction and tangentially to the movement followed by the solid particles; finally, after the coating process, cooling the resulting coated particles so as to solidify the thermofusible agent around the particles.

Abstract: A pharmaceutical composition for oral use is disclosed. It includes, as active principle, a drug liable to undergo a strong first intestinal passage effect and a carrier which is self-micro-emulsifying on contact with an aqueous phase.

Abstract: The invention concerns a composition comprising a microemulsion forming system by contact with a hydrophilic phase brought, after ingestion, by the physiological fluid, said microemulsion forming system comprising: at least an active principle; a lipophilic phase; a surfactant (TA); a co-surfactant (CoTA). The invention is characterized in that said composition further comprises an inert polymeric matrix which cannot be ionised at physiological pH, dispersed in the microemulsion forming system before ingestion, said polymeric matrix being capable, after ingestion, of forming on contacting the physiological fluid, a gelled polymeric matrix enabling to release by diffusion, in continuous and prolonged manner the already micro-emulsified active principle.